Hereditary Central Nervous System/Brain Cancer Panel
Use
This test is for individuals with relevant features who have a clinical or suspected hereditary cause of central nervous system or brain tumors. It also includes those with a diagnosis of medulloblastoma, astrocytoma, meningioma, or glioma, and individuals with a family history of hereditary cancer predisposition syndromes such as nevoid basal cell carcinoma syndrome, Li-Fraumeni, or Neurofibromatosis Type 1.
Special Instructions
Testing options are available for stat processing with a surcharge. Hold testing or reflexive testing options are also provided, with specific order instructions available via the test requisition form.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration, which may affect its availability in certain regions. The performance characteristics are validated by the laboratory following CAP and CLIA regulations.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided